Aristotle University Of Thessaloniki (AUTH)
Μελέτη της λοίμωξης από το ελικοβακτηρίδιο του πυλωρού σε ασθενείς με μυελοδυσπλαστικό σύνδρομο
Abstract
dc:descriptionMyelodysplastic syndromes (MDS) are defined as heterogeneous clonal disorders, caused by intrinsic defects in hematopoietic stem cells; the term MDS includes a diverse group of diseases in which the bone marrow production of blood cells is disrupted. Immunophenotypic aberrancies, along with disorders in the number of peripheral blood (PB) cells are common in this disease. Patients suffer morbidity from associated cytopenias leading to an increased risk of infection, transfusion-dependent anemia and bleeding. In spite of the wealth of information on therapeutic options, little is known about the epidemiology of MDS including risk factors. H. pylori (Hp) is a curved spiral gram negative bacterium that colonizes the gastric mucosa of most humans worldwide, mainly affecting older adults in the developed world including Greece; more than half of the world’s population is infected with this bacterium. It is listed as a class I carcinogen according to World Health Organization, being the leading cause of gastric cancer worldwide. It is associated with various upper gastrointestinal diseases and extra-digestive conditions including idiopathic thrombocytopenic purpura or iron-deficiency anemia. The number of important studies revealing such associations suggests that pathogenic mechanisms may link this infection with many diseases of unknown etiology. To determine the frequency of Helicobacter pylori infection (Hp-I) in 73 patients with myelodysplastic syndromes (MDS) and 40 controls, Hp serologic analysis and ¹³C-urease breath test (INFAI) were evaluated. Gastric mucosal biopsy specimens were obtained for Hp-I presence by rapid urease test (CLO) and Cresyl violet staining. Peripheral blood (PB) flow cytometry for CD3, CD4, CD8, CD14, CD19 and CD34 was conducted in 35 patients and in controls. When compared with controls, Hp-I was detected by: (a) serology in 75.34% of patients (p=0.000), (b) INFAI in 57.69% of patients, (c) CLO in 60.71% of patients and (d) histological confirmation in 80.36% of patients (p=0.001). No correlation between expression of CD3, CD4, CD8, CD14, CD19, leukaemic transformation or death and Hp-I was observed. However, in 20 cases, significant variation in the PB lymphocytic proportion was ascertained, in contrast to the expected MDS ratio, possibly attributed to Hp-I. In conclusion, the increased prevalence of Hp-I among the MDS patients is an interesting finding, hinting that there might be a link between Hp-I and MDS and requiring further investigation. This may indicate a common factor causing susceptibilities to both MDS and Hp-I or that Hp might influence MDS pathophysiology. However, there is no evidence of an existing causal relationship between Hp-I and MDS, although such a possibility cannot be entirely ruled out. The prospect of a chronic Hp-I causing continuous stimulation, fatigue and distress of the bone marrow deposits, thereby leading to alterations facilitating the induction of MDS, is intriguing.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Diamantidis, Michael
- Διαμαντίδης, Μιχαήλ
Subjects
dc:subject × 22- Μυελοδυσπλαστικό σύνδρομο
- Ελικοβακτηρίδιο πυλωρού
- Ασθενείς
- Μάρτυρες
- Επιπολασμός
- Λεμφοκυτταρικοί υποπληθυσμοί
- Κυτταρομετρία ροής
- Διάγνωση - ιστολογικό κομμάτι
- Myelodysplastic syndromes
- Helicobacter pylori infection
- Patients
- Controls
- Prevalence
- Lymphocytic subpopulations
- Flow cytometry
- Diagnosis - histology
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/33141